The US HIV Cure Academy connects people affected by HIV with leading researchers to explore the latest HIV cure strategies and equip them with the skills needed to prepare their communities to engage in HIV cure research.  

→ Read highlights from the 2026 US HIV Cure Academy! 

The World Needs an HIV Cure, and Cure Research Needs Community Input 

More than a hundred HIV cure clinical trials with thousands of participants are underway. An effective HIV cure will reduce new infections, neutralize stigma and discrimination, contribute to the end of the epidemic and provide hope to millions of people living with HIV. But cure research is highly complex and the trials to test possible solutions involve careful considerations that communities must understand. People affected by HIV have an opportunity to play a fundamental role in shaping a research agenda that reflects community priorities and ensuring communities understand and support research.

About the HIV Cure Academies 

AVAC convenes two HIV Cure Academies each year— the US HIV Cure Academy and the Advocacy-For-a-Cure Academy hosted with the International AIDS Society (IAS). The Academies prepare civil society to fight effectively for research that matters to the people who are most impacted by HIV. AVAC co-hosts the US HIV Cure Academy in the US through the Martin Delaney Collaboratories (MDCs) community engagement program under REACH, PAVE and I4C, with support from additional partners. Previous partners include the Collaboratory of AIDS Researchers for Eradication (CARE), BEAT-HIV, CRISPR for Cure and The Well Project. Each year, the US Academy brings together roughly 20 people affected by HIV and leading cure researchers to explore current strategies under investigation and the implications for different populations. They consider the challenges in cure research, approaches to broad stakeholder engagement and strategies for accelerating the design, social acceptability and rapid adoption of HIV cure products.

The program: 

• Provides training on current HIV cure research strategies, barriers to a cure and skills for communicating scientific results accurately to communities that will most benefit from cure research.
• Supports the development of tools to broaden cure literacy to the wider community, including policy makers, the media and program managers.
• Creates opportunities to interact with leading researchers and other people affected by HIV with a view to expanding the civil society network supporting HIV cure.

The Cure Fellowship

Following the Academies, AVAC awards at least one fellowship to Academy alumni to support the development of a project that meets one of the following criteria:

• A program to build support for HIV cure research in-country;
• Strengthens networks and tools for cure advocacy in local contexts;
• Develops and provides HIV cure education and information for clients, advocates and healthcare providers

Learn more about the 2026 Alumni Fellows.

Impact 

Since 2025, 40 advocates have participated in the US HIV Cure Academy. The majority represent communities across the US that are most burdened by HIV. Academy alumni have gone on to serve on community advisory boards and support better understanding of HIV cure science in their communities. They make the science accessible and promote community support for accelerated research in their local context. Furthermore, they identify and inspire future Academy participants, growing the field of cure advocates.

Contact

For more information on this program, reach out Jessica Salzwedel at [email protected]. 

This work is supported by the National Institutes of Health, grant numbers UM1AI164556, UM1 A164565 and UM1AI164566.

Overview

An experimental monthly pill, called MK-8527, now known as alimatravir, is in Phase 3 efficacy trials for HIV prevention. Known as the EXPrESSIVE program, these clinical trials represent a bold new program to expand the toolbox for HIV prevention with an innovative option that could fill a critical gap alongside daily pills, a monthly vaginal ring and longer-acting injections.

AVAC’s Role

With support from the Gates Foundation, AVAC has worked to influence the design of the Phase 3 trials and their implementation, and ensure strong engagement with community representatives in the alimatravir program. Since 2024, AVAC has convened stakeholders to help shape trial design, operational aspects of the alimatravir efficacy program, and advance critical issues, including possible use of alimatravir as PEP and its uptake by people who use drugs. AVAC, working closely with community-based organizations, also oversaw a transformative human-centered design process to develop educational materials for one of the trials. These efforts coincide with broader AVAC efforts to engage advocates and other drivers in preparation for results of the EXPrESSIVE program, and, in the case of positive results, building the foundation for a swift path to wide-scale uptake and access to a monthly oral prevention option.

Objectives

• Ensure the trial follows Good Participatory Practices: Support a cadre of informed, engaged advocates who serve as effective liaisons throughout the EXPrESSIVE program, ensuring smooth trial conduct and readout, clear articulation of next steps, and responsiveness to community and other key stakeholders.
• Plan for accelerated access: Ensure stakeholders’ perspectives and priorities are incorporated into the efficacy program and accelerated access planning well in advance of efficacy results so that trial conduct and implementation programs are smooth and community-centric, and no time is lost if trial results are positive.
• Socialize the concept of a monthly PrEP pill in focus communities early: Develop communications materials to support awareness and understanding of alimatravir, including trial education and access planning. 
• Mobilize a comprehensive ARV strategy: Promote and draw consensus around a comprehensive policy, advocacy and communications strategy to support ARVs in all their forms – PrEP, PEP and treatment, with a particular focus on long-acting methods.

Project Materials

AVAC has produced several resources to explain and contextualize the EXPrESSIVE program and the monthly PrEP pill.

• Go to PrEPWatch.org’s dedicated page on MK-8527 for background information on the product and details on the EXPrESSIVE trials.
• Next Up: A monthly pill for PrEP?: This episode of AVAC’s PxPulse podcast features MSD’s Distinguished Scientist Rebeca Plank and AVAC’s Regional Manager for Research Engagement Grace Kumwenda. They explain the trials’ design, why a monthly pill could be so important to HIV prevention and how GPP is shaping both R&D and rollout of the trials.
• EXPrESSIVE Phase 3 Trials tracks the status of study enrollment in the 17 countries hosting trial sites for the two efficacy trials.
• The EXPrESSIVE-11 clinical trial page showcases AVAC’s work on communications materials and is a resource for potential participants to learn more about the trial.

EXPrESSIVE Program

Under the EXPrESSIVE program, alimatravir, an investigational ARV drug, is being studied as a potential PrEP product. EXPrESSIVE-10 is enrolling approximately 4,580 cisgender women and adolescent girls and young women (AGYW) aged 16–30 in Kenya, South Africa and Uganda. EXPrESSIVE-11 is enrolling approximately 4,390 men who have sex with men (MSM), gender non-binary individuals, and transgender individuals in 17 countries in the Americas, Africa, Asia and Europe. Results from the trails are anticipated in mid-2027.

“This is not just another trial; it’s a signal that the needs of young women and other key groups most affected by HIV really matter. A monthly pill will offer a new kind of freedom – something discreet, something manageable, something we can own on our terms.”

Chilufya Kasanda Hampongo

Chair of the Young Women’s HIV Prevention Council (YWHPC)

“Choice is the superpower in HIV prevention. Even with injectable CAB and LEN, we still have gaps, and a monthly pill will add a vital option. We need ongoing research to fill these gaps in prevention; not everyone wants or will be able to access an injection, and daily pills don’t work for many people in need. It’s about options and access.”

Nandisile Sikwana

AVAC’s Regional Stakeholder Engagement Manager based in South Africa and a member of the EXPrESSIVE-10 Global Community Accountability Group (GCAG)

“As the Global Community Advisory Group for EXPrESSIVE-10, we are committed to ensuring that this trial is both scientifically sound and deeply rooted in the actual realities of the African communities it aims to serve. As a GCAG, we will strive to uphold the Good Participatory Practices from the initial design to results dissemination, as well as amplify community voices, and advocate for timely, equitable access if MK-8527 is shown to be effective. Our responsibility is to ensure that research protects communities, and that innovation is matched with real-world impact.”

Simon Odiwuor Ondiek

Former Chair, EXPrESSIVE-10 GCAG

“Access to existing and new products is not optional; it’s a fundamental right. HIV prevention will only achieve impact if everyone who needs it can access it. Populations who contribute their time and their bodies to research — gay, bisexual, MSM, trans, non-binary, AGYW – must benefit first. Access cannot wait until a trial ends; it must be built into every step, from research to delivery.”

Rena Janamnuaysook

Leading HIV prevention advocate based at the Institute of HIV Research and Innovation (IHRI) in Bangkok, Thailand

prev next

Why Now?

Global rates of new infections remain high, even as the options for proven prevention increase. Trials to test new HIV prevention methods continue to be imperative, to ensure that communities in need of prevention will be able to find choices that work for them. 

As daily and long-acting PrEP products roll out, innovative trial design is a focus and challenge for the field. Advocates and communities must play a central role in shaping future trial design. Their input is essential for both community acceptance of clinical trials and for trial results that advance the field. As trial designs grow more complex, this need is greater than ever.

About This Project

Launched in September of 2019, AVAC’s Trial Design Academy convenes HIV prevention advocates from across the globe to confront the technical challenges, engage with researchers, statisticians, product developers and regulators, and help shape the decisions to move the research agenda forward.

The academy is built on the belief that meaningful community engagement is critical. This is why it draws on frameworks like the People’s Research Agenda and the Good Participatory Practice to ensure that trial design and conduct is transparent, inclusive and aligned to community priorities.

Meet the members of the Trial Design Academy.

Ethical Guidance

• HPTN Ethics Guidance Research — The updated guidance covers ethical considerations and their integration into the design and implementation of HIV prevention research.

• Ethical Guidance in Focus — This blog post by AVAC’s Jeanne Baron highlights and compares what’s new in two updated guidance documents, from UNAIDS/WHO and the HPTN, both addressing where PrEP fits in HIV prevention trials

For more information contact [email protected].

Ending the HIV epidemic will, ideally, include a safe, effective and durable cure for those living with HIV. HIV cure research is advancing the understanding of the immune system, driving discovery of innovative testing and monitoring technologies, and supporting the development of new therapeutics. It’s vital for advocates to understand the science and ethics of HIV cure research and to champion equity in research, development and, ultimately, access to cure interventions of the future.

Since 2017, AVAC has helped to advance global and country-specific HIV cure research and advocacy agendas that are community-centered, ethically-based and scientifically rigorous. AVAC’s cure initiatives aim to:

1. Cultivate and support informed cure advocates who are actively engaged with the HIV cure research landscape nationally, regionally and globally.
2. Develop and disseminate new tools that translate complex cure research for the field and advance cure research advocacy.

Advocacy Champions for HIV Cure Research

HIV cure research must center communities of people with and affected by HIV. With knowledgeable and passionate advocates engaged in cure research at the basic and clinical research phases, future trials can be designed to successfully test strategies that align with community needs. Advocates also play a critical role in influencing policies, funding and infrastructure that support HIV cure research.

AVAC’s investment in cure champions includes:

• The Martin Delaney Collaboratories for HIV Cure Research (MDC)
  The NIH-funded MDCs are the largest collaborations focused on HIV cure globally and the flagship NIH research program advancing cure science. The MDCs foster dynamic, multidisciplinary collaborations among academic researchers, industry, government and community partners to pursue cure strategies for HIV. AVAC leads community engagement for three of the ten collaboratories—REACH, PAVE and I4C. AVAC disseminates research literacy materials, convenes dialogues and trainings, and facilitates opportunities for communities to influence cure research from the earliest stages. These efforts ensure cure strategies are developed with meaningful input from a broad range of stakeholders affected by HIV.

• Advocacy-For-A-Cure Academies
  AVAC facilitates two HIV Cure Academies annually: the Global Advocacy-For-a-Cure Academy with the International AIDS Society (IAS) and the US HIV Cure Academy in the US through the Martin Delaney Collaboratories (MDCs) community engagement program under REACH, PAVE and I4C, with support from additional partners. These programs identify and nurture civil society leaders to fight effectively for the development of supportive research environments and the ethical involvement of impacted communities in clinical research. Academy attendees and leading cure researchers explore current investigational strategies, population-specific considerations and effective strategies for translating cure science to a variety of stakeholders. They consider the challenges in cure research, approaches to broad stakeholder engagement and an advocacy agenda to accelerate the design, social acceptability and rapid adoption of HIV cure products. Read highlights from the 2025 Advocacy-for-a-Cure Academy and 2026 US HIV Cure Academy.

• The African HIV Cure Consortium
  The African HIV Cure Consortium includes seven partners (African Alliance, AVAC, CIDRZ, HCAAP, GGTI, IAS and SANTHE) working together to accelerate HIV cure research in Africa. The group advances advocacy by raising awareness, creating and tracking metrics, and working with communities to create advocacy and scientific agendas. AVAC’s role, in partnership with IAS, is to cultivate advocacy hubs by providing strategic grants and mentorship to academy alumni. In addition, AVAC is tracking the state of HIV cure research and mapping cure research assets in Kenya and South Africa in order to address barriers and advance opportunities to conduct cure research in these countries.

Cure Literacy Tools

Accurate information on cure research enables stakeholders, including affected communities, to engage with critical questions facing the field. AVAC and partners produce literacy content on the scientific fundamentals and challenges driving the field forward. Advocates engaged in cure research rely on these materials to stay informed and prepared.

AVAC Cure Literacy Tools

• What Does it Take to Conduct HIV Cure Research?
• HIV Cure Strategies (coming soon)
• Sex & HIV Cure Research
• Cure Research Cohort Map

Partner Spotlight

HIV Cure Academy alumni Doreen Moraa, Josephine Nabukenya and Skegabo Seselamarumo are leading voices for young people to turn to for HIV cure information, with thousands of followers across various social media platforms. These alumni engage with prominent researchers to create novel digital materials, including videos and podcasts, to explain the state of HIV cure research in Africa and connect scientific advances to everyday lives.

HIV Cure Academy alumni Elina Mwasinga and Lusungu Harawa organized the first HIV cure agenda setting workshop in Africa to identify barriers and opportunities for cure research in Malawi. The workshop was conducted in collaboration with the Malawi National AIDS Commission and Ministry of Health.

The PAVE Community Advisory Board created an African-wide storytelling campaign to share the importance of HIV cure research from the perspective of young people.

Partner Resource Library

• Women and HIV Cure Resources — a resource from The Well Project that focuses on women’s unique contributions in cure research and highlights the lived experiences of women
• CUREiculum — learning modules and tools that simplify the science of HIV cure-related research to strengthen community engagement in HIV cure research, created by the MDC CAB, AIDS Treatment Activists Coalition, AIDS Action Baltimore and the Treatment Action Group
• CROI 2026 HIV Cure Reflections — a PAVE and REACH video series with HIV cure-related takeaways from CROI 2026
• HIV Cure and the Environment — a REACH webinar recording discussing how the environment may impact HIV cure strategies
• PAVE Voices Project — a PAVE video documenting what an HIV cure means to youth advocates
• CROI 2025 HIV Cure Reflections — a PAVE and REACH video series with HIV cure-related takeaways from CROI 2025
• The Series of JoJo — a culturally tailored video series by Josephine Nabukenya, HIV Cure Academy alumni, on the basics of HIV cure science
• Skegabo Podcast — HIV Cure Academy alumni Skegabo Seselamarumo’s YouTube channel translates complex HIV cure science into accessible, community-centered conversations

Overview

Advances in long-acting PrEP represent unprecedented opportunities to bend the curve of the HIV epidemic, if unprecedented investment and coordination focus on reaching key populations (KPs). Key populations, including gay men and other men who have sex with men, trans and gender non-binary individuals, sex workers, and people who use drugs, are consistently marginalized from health services. While they account for 55% of people acquiring HIV globally, and 80% outside of sub-Saharan Africa, UNAIDS data show only 40% of men who have sex with men, 39% of transgender individuals, 39% of people who inject drugs, and 50% of sex workers who were at risk of HIV were accessing effective prevention. Reaching these communities is central to making a meaningful impact in the reduction of HIV incidence globally.  

About this Project

PrEP Power, a project led by Global Black Gay Men Connect (GBGMC), supported by the Global Key Population Advisory Group (KPAG), and with technical support from AVAC and Access Bridge, is spearheading efforts to ensure KPs have equitable and effective access to the full range of HIV prevention options, including long-acting PrEP.

PrEP Power will coordinate market assessments, demand forecasting, human centered design research, community education, and demand generation to address barriers to long-acting PrEP access by KPs.  

Gathering the right data and committing resources to fully understand how to deliver new prevention options, such as injectable cabotegravir (CAB), the dapivirine vaginal ring (DVR), and lenacapavir (LEN), and perhaps the monthly oral pill MK-8527 in the future if successful in the current trials, could increase effective HIV prevention coverage among KP communities.

Impact

AVAC’s support of this project will help uncover some of the major factors that support or obstruct PrEP access for KPs, help create accurate demand forecasts to support efficient production of long-acting PrEP, and ultimately, increase access to and uptake of long-acting PrEP. 

More Information

Visit the PrEP Power website or reach out to Cat Verde Hashim at [email protected].

Civil Society for key populations (KPs) must overcome significant challenges in their advocacy. Stigma, discrimination, disinformation, repression, criminalization, violence, and economic inequities burden and marginalize LGBTQIA+ people, sex workers, people who use drugs and other key populations who are vulnerable to HIV exposure. The KP-TNC fosters a community of practice and builds coalitions to develop strategies and advance advocacy for global health equity at large, and for HIV prevention and treatment among key populations.

About This Project

The KP-TNC is made up of consortiums of KP-led organizations in eight countries: Ghana, Kenya, Malawi, Nigeria, South Sudan, Tanzania, Zambia and Zanzibar. It plays a crucial role in strengthening relationships between KP organizations and development partners, regional organizations, the African Union, PEPFAR, The Global Fund and country governments. The latter holds special importance for TNC members who operate in countries where discrimination and criminalization of key populations has posed a serious barrier to advocacy. These constraints have undermined the development of effective policy and programs, depriving policy makers of essential impute from key populations  on the design and implementation of programs aimed at delivering health services to them. The work of the KP-TNC is shoring up these critical failings with deeply informed, well resourced KP-led organizations who bring innovation and solutions that work.  

The KP-TNC provides members with strategic training & education, and offers a platform for developing best practices. Advocacy is focused on PEPFAR’s Country Operational Plans (COPs), the Key Population Investment Fund (KPIF), other global, regional or country process for health programming, and expanding KP leadership in the design, implementation and evaluation of programs that deliver healthcare services to key populations. 

Efforts to prepare for the next pandemic are changing the trajectory of global health. Governments around the world are coordinating on a range of agreements to meet the challenge of future global health threats. For Pandemic Prevention, Preparedness and Response (PPPR) to succeed, it is imperative that lessons from the HIV response are integrated into the architecture being built for PPPR. This means principles of equity must be embedded at every level of these agreements, and governments and civil society must be empowered to hold each other accountable to their commitments. The HIV response is inextricably linked to the progress or failure of PPPR. If done correctly, engaged and supported civil society and an integrated, fully funded response to HIV and the globes other current pandemics become the foundation for PPPR to effectively respond to emerging threats. 

About this Project

HIV advocates bring essential expertise to advocacy for PPPR. AVAC works in partnership to track the process and content of these agreements. Through collaboration, we identify gaps, develop an advocacy agenda and put forward concrete proposals. We champion key priorities aimed at ensuring principles of equity guide the structure and operation of the global architecture for PPPR that is being built in the aftermath of the COVID-19 pandemic.

In a reimagined vision for pandemic readiness and global health, each country contributes their fair share, based on resources available, to be distributed globally, with priority for serving those most in need and achieving global health equity. As we saw during the COVID-19 Pandemic, richer countries have long abandoned global public health concerns once they consider the situation to be under control in their own countries (as with HIV, TB, malaria, and other infectious diseases). This isolationist approach must end: until access to essential health services and biomedical interventions is equal for all, we are all vulnerable to new health threats.

There is a significant opportunity to harness new initiatives and reform existing infrastructure to better address health issues, recommitting the world to the primary health care (PHC) measures outlined in the Astana Declaration and prioritizing health systems strengthening. There is growing recognition of the interrelated nature of global health and the need to integrate health responses between disease areas and with trade, education, labor, and finance. Resources for PPPR have historically been too little and too focused on infrastructure (laboratory capacity, gene sequencing functionality, and surveillance) while donor countries typically see PHC and health systems strengthening as an in-country responsibility. Multilateral-driven policy initiatives and platforms such as the WHO Pandemic Accord, new Pandemic Fund, and UN PPPR High-Level Meeting (HLM) present a great opportunity to, for the first time, collectively fund and strengthen health systems and primary health care—if the decisions incorporate lower- and middle-income country (LMIC) and civil society priorities.

Overview

Ending the HIV epidemic depends on political will, committed resources and a policy environment that supports and adequately finances equitable access to HIV prevention research, services, interventions, and products with communities at the center. Nearly four decades of HIV advocacy has shown us the power and potential of a strong ecosystem of partners in creating and sustaining effective local, national and international policies.

About the Project

AVAC and partners founded the Global AIDS Policy Partnership (GAPP) and the Federal AIDS Policy Partnership (FAPP) to create diverse coalitions of organizations who are committed to maintaining and expanding well-resourced, evidence-based HIV treatment and prevention programming and funding at the US and international levels. Through these coalitions, AVAC brings diverse perspectives and expertise to identify policy priorities and support the creation of campaigns to advance them.

The Global AIDS Policy Partnership
As a co-chair of the Global AIDS Policy Partnership (GAPP), AVAC helps the 70-member coalition expand and improve US global HIV/AIDS programming through PEPFAR and the Global Fund. The GAPP is comprised of more than 70 US organizations—including advocates, civil society and faith-based organizations, philanthropy, implementers, professional membership organizations, and NGOs.

Federal AIDS Policy Partnership
AVAC is also a member and a co-convener of the Research Working Group of the Federal AIDS Policy Partnership (FAPP), a national coalition of more than 120+ local, regional, and national organizations advocating for federal funding, legislation and policy to end the HIV epidemic in the United States. Much of FAPP’s policy and advocacy work is accomplished through seven FAPP-affiliated working groups. The Research Working Group works to advance the HIV research agenda through relationship building with the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and other HIV research funders, identifying gaps in HIV research, educating policy makers on the value of HIV research (for the field, but also for the broader research enterprise), and increasing federal funding through advocacy and coalition building.

Global Health Technologies Coalition
AVAC co-founded and participates in the Global Health Technologies Coalition (GHTC), a coalition of more than 40 organizations and institutions advocating for US and multilateral policymakers to enact policies and investments to accelerate development of health technologies that are affordable and accessible to the communities who need them.

Applications

AVAC is no longer accepting applications for 2024 Advocacy Fellows.

If you’d like to learn about the program and what is involved, please see the Application materials available here.

Overview

Well-supported advocates keep the global response to HIV on track. Effective HIV prevention depends on programs and research that are fundamentally grounded in the needs and priorities of people who need prevention most. Passionate, skilled community advocates are the lynchpin to this process. They explain the science, define priorities, hold stakeholders accountable and influence the field.

About AVAC Advocacy Fellows

More than 10 years ago, AVAC launched its first Advocacy Fellows program to identify emerging HIV prevention champions, support their efforts, help hone their skills, strengthen the capacity of civil society to shape the agenda for HIV prevention research and influence how fast new interventions move into policy and programs. Today, the Advocacy Fellows program continues, offering 12 – 18 months of intensive support to emerging and mid-career advocates to complete an advocacy project focused on HIV prevention and global health equity—from research to programs to structural interventions that address human rights.  

AVAC provides technical and financial support to Fellows—both salary and project budget—for the duration of the Fellow’s year. The Fellows program is implemented through a close collaboration among the Advocacy Fellow, the Host Organisation and AVAC. 

Advocacy Fellows are housed by “Host Organisations” who are the fiscal and administrative grant partners. Hosts provide daily supervision to Fellows, ensure their projects are aligned with the organization’s goals and ensure that their activities and strategies are contextualized in the country/community.

Impact

Since launching in 2009, nearly 100 alumni fellows from 70+ partner organizations across 15+ countries have participated in the program. They have gone on to change policy, champion community perspectives, help strengthen healthcare systems, demystify HIV prevention research, and insist on fairness and transparency locally, regionally and globally.

Celebrate ten years of the Fellows program with us, read the independent evaluation of the program, and learn where the Fellows are now.

I had no knowledge about good planning, accountability and execution of a good project. But with the assistance of the fellowship team at AVAC, as I write now, I feel I am one of the most supersonic HIV cure advocates the world has ever seen!

Moses Supercharger

2017 AVAC Advocacy Fellow

The AVAC Fellowship turned a naive nurse to a robust advocate. Now I can advocate for anything that I believe is right, even if I may be the only man standing and be unpopular… South African’s U=U scale up would not be where it is now if it was not for what I started then [when I was an AVAC Fellow].

Mandisa Dukashe

2020 AVAC Advocacy Fellow

prev next

Overview

Discussion, debate, and information sharing has been core to HIV advocacy and activism for over four decades resulting in many hard fought global gains in HIV treatment and prevention. 

Today, as we work to make complex science accessible, identify where advocacy and action are needed, and pursue bold national, regional, and international agendas that improve global responses to HIV and prepare to prevention future pandemics, we need a space to come together.

About the Project

The Choice Agenda provides such a space—it is a new global forum for advocacy on the latest in HIV prevention. With monthly webinars hosting highly-informed discussions with advocates and experts across the field and a moderated listserv of over 2,800 subscribers from 40 countries, the Choice Agenda platform is serving as an essential space for the HIV prevention community to come together to discuss, debate and chart the way forward. 

The Choice Agenda program, and all of its participants take on a wide range of topics. Together, the TCA community drills into critical choices, including the need for short acting, non-systemic, user-controlled options, and a wide range of tailored implementation strategies that must define advocacy, the HIV response, and global health equity at large. Participants are also provided with links to a curation of exceptional resources to support further education and advocacy.

Join the Listserv

Join in on agenda-setting conversations. Members are encouraged to share their opinions and concerns and contribute to discussions and debates in the space. They can also reach out with suggestions about webinar content and speakers. Reach out to Jim at [email protected] to be added to the list.

The Webinars

The Choice Agenda hosts monthly webinars and moderates passionate, highly-informed discussions with advocates and experts across the field. Upcoming events are above on this page. Recordings are available here. Materials from previous events will be posted soon.

Stay in Touch

Follow along on Twitter via #TheChoiceAgenda and email Jim to join the listserv.

So many interesting threads and important to have a platform where people can voice difficult issues in a frank and challenging way. I am learning so much.

Dr Rachel Baggaley

WHO

Thank you so much Jim for moderating this forum. I want to nominate Jim to be the next PM for Thailand.

Udom Likhitwonnawut

AVAC consultant

prev next